ClinicalTrials.gg
Active, not recruitingNCT06285396Updated Nov 16, 2026

Effect of Ephedrine, Phenylepinephrine, and Norepinephrine on Myometrial Contractility in Pregnant People With Type II and Gestational Diabetes During Cesarean Section: An In-vitro Study

An interventional study of Ephedrine and Phenylephrine in Postpartum Hemorrhage, sponsored by Samuel Lunenfeld Research Institute, Mount Sinai Hospital. Active, not recruiting at 1 site in Canada. Open to female participants aged 19 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by Samuel Lunenfeld Research Institute, Mount Sinai Hospital · Not applicable, Interventional, and Treatment

How we know

Updated Nov 16, 2026Now Active, not recruitingPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
96
Allocation
Randomized
Ages
19 Years to 45 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 34 studies in Postpartum Hemorrhage by Samuel Lunenfeld Research Institute, Mount Sinai Hospital — 5 open to participants now, 6 under way, none of them phase 3. Postpartum Hemorrhage · Samuel Lunenfeld Research Institute, Mount Sinai Hospital.

Planned enrollment
7th of 32
96 · median 40
Started
2024
with 1 other
No phase
32 of 34
5 open now
Registered
29th of 34
by date

Among the 34 studies in Postpartum Hemorrhage by Samuel Lunenfeld Research Institute, Mount Sinai Hospital, this one is the 7th largest by planned enrollment of the 32 interventional ones that give a count, is one of 2 that started in 2024, is one of 32 with no phase, and was the 29th registered.

Postpartum Hemorrhage

471 studies on the registry are indexed under Postpartum Hemorrhage; 76 are open to participants now.

Browse Postpartum Hemorrhage studies →

Open to participants now

5 of the 34 studies in Postpartum Hemorrhage by Samuel Lunenfeld Research Institute, Mount Sinai Hospital are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 41 Postpartum Hemorrhage studies recruiting now, 21 (51%) set no upper age limit and 20 (49%) stop at 75 or younger; 6 take children under 18; 20 take healthy volunteers.

This study: 19 Years to 45 Years · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 34 studies in Postpartum Hemorrhage by Samuel Lunenfeld Research Institute, Mount Sinai Hospital, or all of them as a file.
02

Study summary

The goal of this study is to learn about how medication that is used to help treat low blood pressure during a Cesarean delivery (CD) can cause changes to the uterine muscle tissue and its ability to contract, in patients with Type II and gestational diabetes.

Spinal anesthesia administered during elective CD has been known to cause hypotension (low blood pressure) as a side effect during the procedure, and is prevented by administration of vasopressors (medication to raise blood pressure) by the anesthesiologist after the delivery of the baby. Vasopressors treat hypotension by interacting with receptors on blood vessels that increase blood pressure, which can also cause changes to uterine contractility. Inadequate uterine contraction after CD can expose mothers to postpartum hemorrhage (PPH), with diabetic patients displaying a 2.5-times higher risk of PPH.

It is important to understand how vasopressor(s) might affect the uterine contractility of women with Type II and gestational diabetes. Since medication to contract the uterus is also routinely administered at delivery, it is important to study the effect of these drugs in combination. The purpose of this study is to compare uterine contractility patterns and receptor distribution in women with type II and gestational diabetic and control term pregnant patients with administration of vasopressors. This will be done using small uterine tissue samples taken from the incision site following CD, which will then be used for experiments in the laboratory.

Read the detailed description

The global prevalence of diabetes has increased drastically over the past 20 years, with 1.5 million new cases each year. The prevalence of Type II diabetes in women of childbearing age has shown the greatest increase, in the United States alone rising from 33% in 1990-1998 to 70% in 2020. Additionally, the worldwide rate of cesarean delivery (CD) follows a similar trend. CD procedures can be both elective and emergent, with the rate of elective CD increasing by 30% in Canada since 2001. Neuraxial anesthesia administered during elective CD has been known to induce hypotension as a side effect, which is then countered by administering vasopressors such as epinephrine, norepinephrine, and phenylephrine that act on adrenergic alpha and beta receptors on smooth muscle tissue. However, since these receptors are expressed on the smooth muscle layer of the uterus called the myometrium, vasopressors can elicit changes in myometrial contractility. Inadequate myometrial contractility during CD can expose the mother to postpartum hemorrhage (PPH) which is a leading cause of maternal mortality worldwide.

Additionally, diabetic women undergoing CD are often obese (BMI > 30 kg/m2) or have macrosomia (larger than average baby), which are independent risk factors for PPH. However, there is still a 2.5-fold increased risk in PPH in Type II diabetic patients, even when adjusted for diabetic-associated obesity. Type II diabetics undergoing elective CD also display a reduced contractile profile (as previously explored through in-vitro calcium signaling), which may contribute to their increased risk of PPH. Current research on myometrial contractility shows that throughout the gestational period, the adrenergic receptor subtypes on the myometrial tissue may transition to more pro-contractile phenotypes, which may react differently to administered vasopressors and thus affect induced contractility during CD. Oxytocin, a uterotonic, is the standard treatment for preventing PPH administered immediately after delivery.

There is currently no literature on the unique effects of vasopressors to manage hypotension in obstetric patients who are diagnosed with Type II and gestational diabetes. The increased risk of PPH at CD seen in type II and Gestational diabetics mothers may be due to differences in adrenergic receptor distribution, which have different affinities to the vasopressors administered. No studies thus far have directly explored the role of vasopressors on myometrial contractions in this patient population.

As the use of a standardized vasopressor dosage becomes more routine during elective CD, it is important to understand how this will affect the myometrial contractility of women with Type II and gestational diabetes. The investigators hypothesize that administration of vasopressors in full term pregnant women with type II and gestational diabetes will cause decreased myometrial contractility compared to healthy controls, and that the diabetic tissue will possess a different adrenergic receptor subtype profile compared to controls.

Aim 1: Investigate the differences in myometrial contractility of type II and gestational diabetic vs. control term pregnant patients with administration of vasopressors

Aim 2: Determine the expression of adrenergic receptor subtypes on myometrium of term pregnant type II and gestational diabetic patients

Aim 3: Investigate the difference in downstream adrenergic pathways proteins in myometrial of type II and gestational diabetics vs control patients with administration of vasopressors

03

Conditions studied

  • Postpartum Hemorrhage

Keywords

  • oxytocin
  • type II diabetes
  • gestational diabetes
  • uterine contraction
04

Who can participate

Ages eligible
19 Years to 45 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients who have given consent to participate in the study
  • Patients with gestational age 37-41 weeks
  • Patients previously diagnosed with either Type II or Gestational diabetes. For the healthy control group, no previous diagnosis is required for inclusion
  • Patients of 19-45 years
  • Patients of normal (18-30 BMI) for the healthy control group only
  • Baby is registered as normal weight for size for the healthy control group only
  • Non-laboring patients, not exposed to exogenous oxytocin
  • Patients requiring elective primary or first repeat caesarean delivery
  • Patients undergoing caesarean delivery under spinal anesthesia

Exclusion criteria

Exclusion Criteria:

  • Patients who refuse to give written
  • Patients who require general anesthesia
  • Patients in labor and those receiving oxytocin for induction of labor
  • Emergency caesarean delivery in labor
  • Patients who have had previous uterine surgery involving myometrial dissection or >1 previous caesarean delivery
  • Patients with risk factors for PPH such as those with polyhydramnios, preeclampsia, multiple gestation, morbid obesity, macrosomia (large for size baby), and previous history of PPH. However, for diabetic group, those with morbid obesity and macrosomia will not be excluded as these conditions are almost always associated with diabetes.
  • For the healthy control group only, a >30 or \<18
  • Maternal age >45
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
96 participants (estimated)

Study arms

  • No intervention
    Control

    The myometrial samples are bathed in physiological salt solution (PSS) only.

  • Active comparator
    Ephedrine

    The myometrial samples are bathed in physiological salt solution (PSS) with increasing concentrations of ephedrine.

    Drug: Ephedrine

  • Active comparator
    Phenylephrine

    The myometrial samples are bathed in physiological salt solution (PSS) with increasing concentrations of phenylephrine.

    Drug: Phenylephrine

  • Active comparator
    Norepinephrine

    The myometrial samples are bathed in physiological salt solution (PSS) with increasing concentrations of norepinephrine.

    Drug: Norepinephrine

  • Active comparator
    Control + oxytocin

    The myometrial samples are bathed in physiological salt solution (PSS) and oxytocin.

    Drug: Oxytocin

  • Active comparator
    Ephedrine + oxytocin

    The myometrial samples are bathed in physiological salt solution (PSS) with increasing concentrations of ephedrine and oxytocin..

    Drug: Ephedrine · Drug: Oxytocin

  • Active comparator
    Phenylephrine + oxytocin

    The myometrial samples are bathed in physiological salt solution (PSS) with increasing concentrations of phenylephrine and oxytocin..

    Drug: Phenylephrine · Drug: Oxytocin

  • Active comparator
    Norepinephrine + oxytocin

    The myometrial samples are bathed in physiological salt solution (PSS) with increasing concentrations of norepinephrine and oxytocin..

    Drug: Norepinephrine · Drug: Oxytocin

Interventions

  • Ephedrine in solution, at applicable concentrations based on literature.

  • Phenylephrine, at applicable concentrations based on literature.

  • Norepinephrine, at applicable concentrations based on literature.

  • Oxytocin, at applicable concentrations based on literature.

    Also known as: pitocin

06

What researchers measure

Primary outcomes

  1. Motility index

    Motility index (MI) is a calculated outcome, based on the formula: frequency/(10 x amplitude). Frequency and amplitude are secondary outcome measures as described below. The analysis is undertaken by attaching myometrial strips between an isometric force transducer and the base of an organ bath chamber.

    Time frame: 4 hours

Secondary outcomes

  1. Amplitude of contraction

    The maximum extent of uterine muscle contraction, measured in grams (g). The analysis is undertaken by attaching myometrial strips between an isometric force transducer and the base of an organ bath chamber.

    Time frame: 4 hours

  2. Frequency of contraction

    The number of contractions in uterine muscle (myometrium) over 10 minutes, spontaneously and in response to an agonist. The analysis is undertaken by attaching myometrial strips between an isometric force transducer and the base of an organ bath chamber.

    Time frame: 4 hours

  3. Integrated area under response curve (AUC)

    Time frame: 4 hours

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2024 (actual). Primary completion is estimated for Dec 2027, 45 months after the start.

Of 112 non-industry interventional studies with no phase under Postpartum Hemorrhage, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 28. This study's planned 45 months is above that.

Counting every sponsor, half of 119 studies reached it within 16 months; a quarter within 7 and three quarters within 26.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 16, 2026: primary completion Dec 2026 → Dec 2027 and completion Dec 2026 → Dec 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 22, 2024
First posted
Feb 29, 2024
StartActual
Mar 18, 2024
Primary completionEst.
Dec 2027was Dec 2026
CompletionEst.
Dec 2027was Dec 2026
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Nov 16, 2026
Primary completion
Dec 2026→Dec 2027
Nov 16, 2026
Study completion
Dec 2026→Dec 2027
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    Recruiting→Active, not recruiting
    Primary completion Dec 2026→Dec 2027
    Study completion Dec 2026→Dec 2027
    + 3 other changes: verification date, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06285396
Responsible party
Sponsor
First posted
Feb 29, 2024
Start date
Mar 18, 2024
Primary completion
Dec 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Nov 16, 2026

Study contacts

Mrinalini Balki, MD
principal investigator · MOUNT SINAI HOSPITAL

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Ephedrine · Phenylephrine · Norepinephrine · Oxytocin

Start the discussion